Class Decertification Stands In Pa. Neurontin Suit
A Pennsylvania appeals court has affirmed a state court's decision to decertify a class action accusing Pfizer Inc. of marketing its blockbuster epilepsy drug Neurontin for off-label uses, but has restored...To view the full article, register now.
Already a subscriber? Click here to view full article